GILEAD SCIENCES, INC. Increase (Decrease) in Income Taxes
GILEAD SCIENCES, INC. (GILD) reported Increase (Decrease) in Income Taxes of $142.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxes · last filed 2026-08-06
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for the quarter ending 2026-06-30 was $171.00M.
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for the quarter ending 2026-03-31 was -$29.00M.
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for the quarter ending 2025-12-31 was -$134.00M, a 125.00% decline year-over-year.
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for the quarter ending 2025-09-30 was -$122.00M, a 209.91% decline year-over-year.
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for fiscal 2025 was -$2.11B.
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for fiscal 2024 was -$732.00M.
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for fiscal 2023 was -$1.77B.
- GILEAD SCIENCES, INC. increase (decrease) in income taxes for fiscal 2022 was -$364.00M.
| Period end | Increase (Decrease) in Income Taxes 3 month | Increase (Decrease) in Income Taxes 6 month | Increase (Decrease) in Income Taxes 9 month | Increase (Decrease) in Income Taxes 12 month |
|---|---|---|---|---|
| 2026-06-30 | $171.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $142.00M 10-Q · filed 2026-08-06 | $8.00M derived: sum of 3 quarters · filed 2026-08-06 | -$114.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$29.00M 10-Q · filed 2026-05-07 | -$163.00M derived: sum of 2 quarters · filed 2026-05-07 | -$285.00M derived: sum of 3 quarters · filed 2026-05-07 | -$1.58B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$134.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$256.00M derived: sum of 2 quarters · filed 2026-02-24 | -$1.56B derived: sum of 3 quarters · filed 2026-08-06 | -$2.11B 10-K · filed 2026-02-24 |
| 2025-09-30 | -$122.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.42B derived: sum of 2 quarters · filed 2026-08-06 | -$1.97B 10-Q · filed 2025-11-07 | -$1.44B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$1.30B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.85B 10-Q · filed 2026-08-06 | -$1.32B derived: sum of 3 quarters · filed 2026-08-06 | -$1.21B derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$552.00M 10-Q · filed 2026-05-07 | -$16.00M derived: sum of 2 quarters · filed 2026-05-07 | $95.00M derived: sum of 3 quarters · filed 2026-05-07 | -$1.08B derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $536.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $647.00M derived: sum of 2 quarters · filed 2026-02-24 | -$524.00M derived: sum of 3 quarters · filed 2026-02-24 | -$732.00M 10-K · filed 2026-02-24 |
| 2024-09-30 | $111.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$1.06B derived: sum of 2 quarters · filed 2025-11-07 | -$1.27B 10-Q · filed 2025-11-07 | -$1.97B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$1.17B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.38B 10-Q · filed 2025-08-07 | -$2.08B derived: sum of 3 quarters · filed 2026-02-24 | -$2.96B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$208.00M 10-Q · filed 2025-05-07 | -$906.00M derived: sum of 2 quarters · filed 2026-02-24 | -$1.79B derived: sum of 3 quarters · filed 2026-02-24 | -$1.81B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$698.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$1.58B derived: sum of 2 quarters · filed 2026-02-24 | -$1.61B derived: sum of 3 quarters · filed 2026-02-24 | -$1.77B 10-K · filed 2026-02-24 |
| 2023-09-30 | -$881.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$909.00M derived: sum of 2 quarters · filed 2024-11-12 | -$1.07B 10-Q · filed 2024-11-12 | -$951.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$28.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$189.00M 10-Q · filed 2024-08-08 | -$70.00M derived: sum of 3 quarters · filed 2025-02-28 | $38.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | -$161.00M 10-Q · filed 2024-05-08 | -$42.00M derived: sum of 2 quarters · filed 2025-02-28 | $66.00M derived: sum of 3 quarters · filed 2025-02-28 | -$413.00M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $119.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $227.00M derived: sum of 2 quarters · filed 2025-02-28 | -$252.00M derived: sum of 3 quarters · filed 2025-02-28 | -$364.00M 10-K · filed 2025-02-28 |
| 2022-09-30 | $108.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$371.00M derived: sum of 2 quarters · filed 2023-11-07 | -$483.00M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$479.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-04 | -$591.00M 10-Q · filed 2023-08-04 | ||
| 2022-03-31 | -$112.00M 10-Q · filed 2023-05-03 | |||
| 2021-12-31 | -$361.00M 10-K · filed 2024-02-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |